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The red blood cell (RBC) antigen Wra is a low-prevalence 
antigen first described in 1953 by Holman and assigned to the 
Diego system in 1995. Because of its low prevalence, Wra is 
usually absent on commercial screening RBCs and antibody 
identification panels. When Wr(a+) screening RBCs are available, 
the corresponding antibody, anti-Wra, is often found in sera from 
healthy individuals, patients, and pregnant women. Anti-Wra 
can cause both hemolytic transfusion reactions and hemolytic 
disease of the fetus and newborn. We describe a fatal acute 
hemolytic transfusion reaction caused by anti-Wra in a patient 
with no other RBC alloantibodies. Serologic investigation showed 
that one of the RBC units the patient received was Wr(a+). 
Immunohematology 2021;37:20–24.
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Wra is the most common low-prevalence antigen (LPA) 
in the white population, and anti-Wra is the most common 
naturally occurring antibody.1 The first case of anti-Wra was 
described by Holman2 in 1953 in a child with severe hemolytic 
disease of the fetus and newborn (HDFN), requiring exchange 
transfusion. Anti-Wra is often identified when Wr(a+) red blood 
cells (RBCs) are available on the screening or identification 
panel RBCs, but the antibody is otherwise rarely involved in 
serious hemolytic transfusion reactions (HTRs) or HDFN, 
other than in isolated case reports.3–12 There is, therefore, 
a high consensus in the transfusion community regarding 
the lack of justification for the inclusion of Wr(a+) RBCs on 
commercial screening and panel RBCs.13–15
The prevalence of Wra has been estimated to be 0.064 
percent (1 in 1570) in Norwegian blood donors,16 1 in 1000 in 
the British population, and 1 in 785 in the Spanish population.17 
In a study of Brazilian blood donors,18 the prevalence of Wra 
was estimated to be 1 in 1662. The authors found that the 
prevalence of anti-Wra was 1 in 31, similar to that found in 
Spanish blood donors, but higher when compared with other 
studies.13,19 In different patient settings, the prevalence of anti-
Wra is much higher, such as in antibody-induced hemolytic 
anemia,20 where anti-Wra can be found in 1 in 2 to 1 in 3 
patients with autoimmune hemolytic anemia.21
Based on the low prevalence of Wra, Wra incompatibility in 
the European population is expected to occur in ~1 in 150,000 
RBC transfusions.12
Wra is fully developed at birth, but anti-Wra is otherwise 
rarely involved in HDFN. This finding may be because the 
majority of cases of anti-Wra are naturally occurring and, when 
found, are sometimes automatically assumed to be low titer, 
cold reacting, and IgM in class and, therefore, are dismissed 
as being unable to cross the placenta and cause fetal RBC 
destruction. However, studies have shown that anti-Wra often 
includes both IgG and IgM.1 Wra is resistant to the treatment 
of RBCs with dithiothreitol and proteolytic enzymes such 
as papain, trypsin, and ficin. Arriaga et al.17 showed that 51 
percent of anti-Wra identified in pregnant women and patients 
were of immunoglobulin subclass IgG1 or IgG3, which are 
potentially clinically significant. The same authors17 found 
that anti-Wra found in healthy donors is predominantly an 
IgM antibody with or without an associated IgG component.
Anti-Wra is an intriguing antibody, since it differs from 
antibodies against other LPAs in its high prevalence, even 
in patients never transfused or with no known history of 
pregnancy.19 It is believed that the nature of the antibody can 
be both natural and immune-mediated. Naturally occurring 
anti-Wra can be identified with different frequencies in healthy 
individuals, in pregnancy, and in patients, with especially high 
frequency in patients with autoimmune hemolytic anemia20 
and in previously allo-immunized pregnant women.21
We describe a fatal HTR caused by anti-Wra in a 91-year-
old white female patient.
Case Report
A 91-year-old white woman was admitted to the hospital 
after being found on the floor in her home, disoriented and 
complaining of pain in her right hip. She had a medical history 
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of hypertension, hypercholesterolemia, glaucoma, chronic 
renal insufficiency, and esophagitis, among other medical 
conditions. The radiologic investigations after admission 
showed a pertrochanteric fracture in her right hip, and she 
was operated on the same day with osteosynthesis. The day 
after surgery, her hemoglobin (Hb) level fell from 11.5 to 
8.0 g/dL (normal range 12.0–14.7  g/dL) (Fig. 1), and 2 RBC 
units were issued by electronic crossmatch, since the patient’s 
antibody detection test was negative, and she had no known 
RBC antibodies. The first RBC unit was transfused without 
any complication, but when approximately half of the second 
unit had been transfused, the patient started to feel unwell. 
She experienced chills, nausea, arrhythmia, and tachycardia 
(200 beats per minute [bpm]; normal range 60–100 bpm). Her 
body temperature rose from 37 to 38.1°C, and her O2 saturation 
level dropped to 75 percent (normal >95%). The transfusion 
was immediately stopped, and the patient was transferred to 
the intensive care unit. The blood gas analysis showed reduced 
PO2 and increased lactate, and the blood samples taken right 
after the transfusion reaction showed visible hemolysis. 
Laboratory tests showed normal haptoglobin, increased total 
bilirubin (TB), high levels of lactate dehydrogenase (LDH), 
and increased creatinine (Table 1). After stabilization and 
observation for 5 hours, the patient was moved back to the 
ward.
The day after the transfusion, the patient was improving 
clinically except for a persistent reduced diuresis from before 
the transfusion (75 mL during the night) and hematuria. The 
patient received intravenous (IV) fluids, noradrenalin, and 
diuretics. The response to the initial dose of diuretics was not 
adequate, and an increased dose was given to the patient (500 
mg IV infusion during the day), which still did not yield the 
desired response. On day 3 after the transfusion, the patient’s 
clinical condition started to worsen significantly. In spite of the 
treatment with IV fluids and diuretics, the patient continued to 
show almost absent diuresis (<30 mL diuresis per hour after 
3 L fluids IV). On day 4 after the transfusion, the patient’s 
condition deteriorated further, and the patient was barely 
conscious. At that point, her Hb level had dropped to 6.4 g/dL. 
Biochemical investigations at this point showed decreasing 
levels of TB and LDH, but creatinine levels were increasing up 
to 540 µmol/L, ~63 hours after the transfusion (Table 1). The 
patient was not considered a candidate for dialysis because of 
her numerous comorbidities, and she, along with her closest 
family members, was informed of the severity of her condition. 
At this point, active supportive care was terminated. She 
passed away ~90 hours after the transfusion, likely because of 
extensive renal failure caused by the HTR.
Results
The initial serologic workup for suspected HTR was 
performed at the local blood bank, and it included immediate 
spin (IS) and indirect antiglobulin test (IAT) crossmatches. The 
patient’s ABO group, as well as the ABO group of the 2 blood 
units, was confirmed to be correct. The patient was group A, 
D–. The first RBC unit transfused was group O, D–, and the 
second unit was group A, D–. The patient’s post-transfusion 
sample showed hemolysis not present in the pre-transfusion 
sample. The antibody screening and identification tests, as 
well as the direct antiglobulin test (DAT), were negative in 
both pre- and post-transfusion samples (Table 2). On the other 
hand, both the IS and IAT crossmatches showed a positive 
reaction with the second unit in the pre- and post-transfusion 
samples (Figs. 2 and 3). The IS and IAT crossmatches were 
negative when tested with the first RBC unit in both pre- and 





5 17 39 63
Creatinine, 
µmol/L
74.3–107 174 NP 337 444 540




<255 NP 1384 1692 1175 783
Haptoglobin, g/L 0.2–1.9 NP 0.8 NP NP NP
Creatine kinase, 
U/L
<210 NP 1129 NP 1714 293
D-dimer, mg/L <0.75† NP NP NP >4 >4
*Number of hours after transfusion of second red blood cell unit.
†Normal value for the patient’s age.
NP = not performed.
Fig. 1 Hemoglobin (Hb) levels (g/dL) before and after the transfusion 
reaction. 1 = day of admission to the hospital and surgery; 2 = day 
of transfusion (red arrow); 6 = day of death.
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post-transfusion samples (Table 2). Blood samples from the 
patient and the two blood donors were sent to our National 
Reference Laboratory in Blood Group Serology for further 
investigation, and we confirmed the results obtained by the 
local blood bank. Further investigation showed that the 
antibody had both an IgM and IgG component, with titers 
of 32 and 1024, respectively (Table 2). Taking the initial 
results into consideration, we suspected that the patient was 
immunized against an LPA not present on the screening RBCs 
or on the identification panels. Several antibodies against 
LPAs were excluded, such as anti-Jna, anti-Wu, anti-Vw, anti-
Dia, and anti-Nya. Because of a clerical error at our laboratory, 
the blood donor involved in the positive IS crossmatch reaction 
was erroneously typed as Wr(a–), while the patient was typed 
as Wr(a+), resulting in anti-Wra being initially excluded as 
the cause of the HTR. Further investigation was considered 
necessary, and blood samples from the patient and both 
donors were sent to the International Blood Group Reference 
Laboratory (IBGRL) in Bristol, UK. The results provided by 
the IBGRL confirmed the presence of anti-Wra in the patient’s 
plasma, as well as the phenotype Wr(a+b+) in 1 of the 2 donor 
units. No other RBC antibodies were present in the patient’s 
plasma.
The patient had no known history of pregnancies. 
According to the patient’s hospital records, she had only been 
transfused once, in 2001, because of an operation for abdominal 
lipoma. She received 2 RBC units with no complications. Her 
RBC antibody detection test was also negative at that point. 
In an attempt to determine if the patient could have been 
immunized by her previous RBC transfusion, we were able 
to obtain blood samples from the two blood donors from 
whom the patient had received transfusions in 2001. Both 
donor samples were typed as Wr(a–), and the IS crossmatches 
between the patient and the donors were negative.
Discussion
We report the serologic findings and the clinical outcome 
in a 91-year-old white female patient experiencing a fatal HTR 
caused by anti-Wra.
Table 2. Immunohematologic results
Test parameter Patient RBC unit 1 RBC unit 2
ABO, D A1, D– O, D– A, D–
Wra phenotype Wr(a–) Wr(a–) Wr(a+b+)
















IS crossmatch NA Negative Positive (4+)* 
Negative†




RBC = red blood cell; Ig = immunoglobulin; NA = not applicable; DAT = 
direct antiglobulin test; IS = immediate spin; IAT = indirect antiglobulin test.
Fig. 2 Immediate spin crossmatch results of the Wr(a+) red blood 
cell (RBC) donor unit. (A) Pre-transfusion, (B) Post-transfusion. 
*RBCs from the blood tube after RBC unit transfusion. †RBCs from 
the RBC unit. (Strength of reaction: 4+ [maximum] to 0 [negative]; 














Fig. 3 Indirect antiglobulin test crossmatch results of the Wr(a+) 
red blood cell (RBC) donor unit. (A) Pre-transfusion, (B) Post-
transfusion. *RBCs from the blood tube after RBC unit transfusion. 















IMMUNOHEMATOLOGY, Volume 37, Number 1, 2021 23
Fatal HTR caused by anti-Wra
The implementation of the widely used “type and screen” 
approach for pre-transfusion testing, introduced in 1984, led 
to an increased risk for HTRs due to antibodies against LPAs. 
LPAs can be defined as antigens occurring in <1 percent of the 
population.22 The overall risk for an HTR caused by an LPA 
was calculated by Garratty14 to be ~1 in 500,000 transfusions 
and deemed to be acceptably low enough to justify the absence 
of LPAs such as Wra on the routine screening RBCs.23
Wallis et al.13 observed a higher incompatibility incidence 
of 1 in 10,700 incompatible units due to anti-Wra in 1199 
hospital patients. The same authors13 propose three possible 
strategies to manage potential patients with anti-Wra: (1) 
to perform full compatibility testing on all units before 
transfusion, (2) to assume that the risk for HTR caused by anti-
Wra is so small that it may be ignored and the IS crossmatch 
or the computer-guided blood selection can be used, (3) or to 
type all donors for Wra and then perform full compatibility 
testing when selecting Wr(a+) units for transfusion. The first 
strategy is not in use in Norway after the implementation 
of the computer crossmatch in the late 1990s. The second 
alternative is the general current strategy regarding anti-Wra 
and other LPAs, while the third strategy may not be technically 
possible for some blood bank computer systems. Even if the 
risk of a serious HTR due to anti-Wra is very low, the high 
incidence of the antibody in the patient setting may require the 
implementation of preventive measures. Special consideration 
should be taken regarding the management of Wr(a+) blood 
donors. A possible strategy, the one we propose, is to type 
all first-time donors for Wra and then permanently exclude 
Wr(a+) donors from RBC transfusion purposes. There are no 
current national recommendations in Norway regarding the 
typing of donors for LPAs such as Wra, Kpa, or Cob, or any 
recommendation regarding the management of these donors.
Wr(a+) donors could still be accepted as plasmapheresis 
or plateletpheresis donors. In addition, they may become 
“technical donors,” as a source of Wr(a+) RBCs. Because 
the prevalence of Wra in the general population is very low, 
this measure should not be expected to have a deleterious 
effect on blood donor recruitment. The Wr(a+) blood donor 
in this case report was a first-time donor, and no look-back 
was therefore possible regarding the likelihood of hemolytic 
reactions in other patients. For precautionary reasons, the 
donor was permanently deferred. Our patient had both IgM 
and IgG antibodies (Table 2), and the relatively high IgG titer 
was unexpected, bearing in mind that the antibody was likely 
to be naturally occurring. Other causes of immunization 
therefore cannot be excluded. The reaction strength of the IS 
testing differed significantly in the samples taken before and 
after the reaction, indicating a high degree of hemolysis of the 
transfused Wr(a+) unit (Fig. 2). The negative DAT in the post-
transfusion sample was also in accordance with hemolysis 
(Table 2). The strength of the IAT crossmatch was also reduced 
in the post-transfusion sample, but to a lesser extent than the 
IS crossmatch (Fig. 3).
Anti-Wra is not the only potentially clinically significant 
antibody against LPAs. Even if several examples of HTRs 
caused by other antibodies against LPAs have been reported, 
the computer crossmatch is considered to be a safe approach 
for selecting blood units for non–allo-immunized patients.14,24 
On the other hand, this case highlights the importance of an 
extensive serologic investigation, including the IS crossmatch, 
when an HTR is highly suspected, even if the RBC antibody 
detection test and DAT show negative results. In Norway, it 
is common practice to issue RBC units by crossmatch when 
an HTR is suspected and until the immunohematologic 
workup is completed. This practice is recommended even if 
the patient had a negative antibody detection test before the 
transfusion. Once the immunohematologic workup can rule 
out an alloantibody as the cause of the reaction, the RBC units 
may once again be issued by electronic crossmatch.
Several examples of HTRs caused by anti-Wra have 
been described but, to our knowledge, only a few fatalities 
have been reported.3,12 The hemovigilance system in the UK 
(Serious Hazards of Transfusion [SHOT])25 described 10 cases 
of HTRs due to anti-Wra in the period from 2008 to 2011, and 
one of these cases had a fatal outcome. Two further cases, 
one acute and one delayed hemolytic transfusion reaction 
(DHTR) caused by anti-Wra, were reported in the annual 
report26 for 2017, and three cases of DHTR were reported in 
the 2019 annual report.27 In the Norwegian hemovigilance 
system28 Troll, two cases of acute HTRs due to anti-Wra have 
been reported since 2004, in addition to the one described in 
this case report. Neither of the two previous cases had a fatal 
outcome.
The case described here presents an opportunity to 
remind clinicians of the risks of RBC transfusion, even when 
the patient has a negative antibody detection test, and it 
highlights the importance of early recognition of symptoms 
characteristic of an HTR.
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